IDH2 and central nervous system cancer: With the development of molecular pathology in gliomas, several biomarkers are routinely applied to evaluate gliomas including O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, EGFR alterations, Isocitrate dehydrogenase 1 (IDH1) or Isocitrate dehydrogenase 2 (IDH2) mutations, and 1p19q co-deletion as many of these markers have become standard of care for molecular testing and prerequisites for clinical trial enrollment (Rodriguez, Vizcaino & Lin, 2016).